Eureka reports Phase I response data for anti-CD19 T cell therapy in lymphoma

Eureka Therapeutics Inc. (Emeryville, Calif.) reported preliminary data from 17 evaluable patients with CD19-positive, relapsed and refractory B cell lymphoma in a Phase I trial showing that IV ET190L1-ARTEMIS led to seven complete metabolic responses and three partial responses, plus one case of stable disease. ET190L1-ARTEMIS was well tolerated with no cytokine release syndrome (CRS) or neurotoxicity reported in the open-label, dose-escalation, Chinese trial. The data were presented at the American Society of Clinical Oncology (ASCO) meeting in Chicago...